Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.

Marrufo AM, Mathew SO, Chaudhary P, Malaer JD, Vishwanatha JK, Mathew PA.

Am J Cancer Res. 2018 Jun 1;8(6):1050-1063. eCollection 2018.

2.

CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

Malaer JD, Mathew PA.

Am J Cancer Res. 2017 Aug 1;7(8):1637-1641. eCollection 2017. Review.

Supplemental Content

Loading ...
Support Center